Adalimumab biosimilar (Hualan Biological Engineering)

重组抗人肿瘤坏死因子（TNFα）单抗（华兰基因工程）

Report date: 2026/01/09 14:39:46

Base Information

Drug NameAdalimumab biosimilar (Hualan Biological Engineering)
Drug Alias Name阿达木单抗生物仿制药（华兰生物工程）重组抗人肿瘤坏死因子(TNFα)单抗（华兰基因工程）
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPsoriasisArthritisSpondylitis, Ankylosing
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesHualan Ankang Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHualan Ankang Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsPsoriasisArthritisSpondylitis, Ankylosing
Inactive IndicationsN/A

Other Information

ATC CodeL04AB04
Related LinksN/A